Diamond Equity Estimates MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Research analysts at Diamond Equity issued their Q1 2025 earnings per share (EPS) estimates for shares of MAIA Biotechnology in a research report issued to clients and investors on Thursday, November 14th. Diamond Equity analyst H. Diamond anticipates that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.25) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.35) EPS.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.21.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN MAIA opened at $2.26 on Monday. The company has a market capitalization of $57.25 million, a P/E ratio of -1.64 and a beta of 0.32. MAIA Biotechnology has a 52 week low of $0.82 and a 52 week high of $5.99.

Insider Buying and Selling

In other MAIA Biotechnology news, Director Cristian Luput purchased 22,133 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was bought at an average cost of $2.51 per share, for a total transaction of $55,553.83. Following the completion of the acquisition, the director now directly owns 389,483 shares in the company, valued at $977,602.33. This represents a 6.03 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 36.98% of the company’s stock.

Institutional Trading of MAIA Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its position in MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after acquiring an additional 35,821 shares during the period. XTX Topco Ltd bought a new stake in MAIA Biotechnology in the third quarter valued at $31,000. Ground Swell Capital LLC bought a new stake in MAIA Biotechnology in the second quarter valued at $56,000. Mather Group LLC. grew its position in MAIA Biotechnology by 50,150.0% in the second quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock valued at $41,000 after acquiring an additional 12,036 shares during the period. Finally, Virtu Financial LLC bought a new stake in MAIA Biotechnology in the first quarter valued at $71,000. 5.65% of the stock is currently owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.